Baxalta to Shire: We're young, we're just starting to grow, and we're rejecting your buyout offer

Baxalta CEO Ludwig Hantson

On Tuesday, Shire ($SHPG) went public with a $30 billion bid for Baxalta ($BXLT) that had already been rejected once. And the second time around, Baxalta had the same answer: It's not happening.

Shire's $45.23-per-share bid "significantly undervalues" the young company, Baxalta said late Tuesday, especially since it's just that--young.

"As a new, publicly-traded entity only since July 1, we are just in the initial stages of implementing our growth strategy as a standalone company and our stock has not yet achieved a price level that appropriately reflects the company's value and prospects," Baxalta CEO Ludwig Hantson wrote in a letter to Shire chief Flemming Ornskov. 

Diving into a merger just a month after spinning off from parent company Baxter International ($BAX) "would be severely disruptive," Baxalta Chairman Wayne Hockmeyer added in a statement.

But its youth isn't the only reason the Illinois pharma sees a Shire buyout as a no-go. Unlike the Irish pharma--which touted a deal's prospects for creating a "global" leader in rare diseases--Baxalta doesn't view a tie-up between the two as complementary--nor does it think either company's portfolio would benefit.

Most importantly--as far as shareholders are concerned--"we do not think the combination would generate substantial operational or revenue synergies, which would be critical to any potential value creation," Hantson wrote.

Baxalta's confidence in its standalone strategy comes despite a reliance on its hemophilia drugs--which, ever since Biogen ($BIIB) rolled out a pair of long-acting contenders last year, have been facing stepped-up competition. The rivals are only set to multiply, with Bayer and Novo Nordisk ($NVO) also working on next-gen meds, though Baxalta has its own coming up the pipeline, too--and so far, Biogen's haven't triggered the volume of patient-switching that some analysts predicted.

Meanwhile, the ball is now in Shire's court, and the Dublin drugmaker knows a thing or two about dealmaking back-and-forth. Last year, it rejected multiple advances from AbbVie ($ABBV) before settling on a $55 billion transaction--only to see that agreement scuttled when the U.S. imposed new, stricter rules on tax inversions.

- read Baxalta's release

Special Reports: Pharma's top 10 M&A deals of 2014 | The 25 most influential people in biopharma in 2015 - Flemming Ornskov - Shire

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.